The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2024 | Results of a Phase I study of belantamab mafodotin in combination with KRd for treating myeloma
Shebli Atrash, MD, Levine Cancer Institute & Atrium Health, Charlotte, NC, discusses the results of a Phase I trial (NCT04822337) evaluating belantamab mafodotin in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) for the treatment of multiple myeloma (MM) after 1-3 prior lines of therapy. As the results were promising, this combination will move into Phase II testing. Dr Atrash also briefly comments on how the addition of belantamab mafodotin may benefit patients with high-risk disease and how the use of BCMA-targeting therapies in the frontline may impact subsequent therapy following relapse. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
